Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib in advanced solid tumors after prior FGFR inhibitor
jRCTs041230105Active, not recruiting
- Start
- Dec 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of pemigatinib in Nonhematologic neoplasms. Primary endpoint: Best overall effect up to 16 weeks after treatment initiation. Started Dec 2023; status: active, not recruiting.
02
Drugs
pemigatinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCTs041230105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041230105.